STO · SPRINT.ST
Sprint Bioscience AB
SEK 3.63+SEK 0.13 (+3.71%)
Sprint Bioscience AB’s quoted price sits in the upper half of its reported 52-week range, 20.92% below the high.
Loading market information…
STO · LXB.ST · SEK
Stock price, earnings
Quote as of Oct 30, 2026, 08:35 AM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Luxbright AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 92.85% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Luxbright AB (publ)’s next earnings report is currently expected on Feb 19, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Luxbright AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Luxbright AB (publ), a technology-driven enterprise headquartered in Gothenburg, Sweden, specializes in engineering and marketing X-ray tubes, generators, and comprehensive X-ray systems. Established in 2012, the company's primary focus is on providing these advanced components to other system manufacturers.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:46 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 3.63+SEK 0.13 (+3.71%)
Sprint Bioscience AB’s quoted price sits in the upper half of its reported 52-week range, 20.92% below the high.
SEK 16.70-SEK 0.20 (-1.18%)
Scandinavian Real Heart AB (Publ)’s quoted price sits in the lower half of its reported 52-week range, 29.54% below the high.
SEK 12.50-SEK 0.15 (-1.19%)
SciBase Holding AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 76.85% below the high.
SEK 1.29+SEK 0.04 (+3.2%)
Iconovo AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 29.51% below the high.
SEK 7.98-SEK 0.02 (-0.25%)
Arcoma AB’s quoted price sits in the lower half of its reported 52-week range, 20.6% below the high.
SEK 0.33-SEK 0.00 (-0.6%)
IDL Diagnostics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 37.17% below the high.
SEK 1.57-SEK 0.00 (-0.32%)
Pila Pharma AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 37.4% below the high.
SEK 0.05+SEK 0.01 (+13.0%)
Spago Nanomedical AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 78.48% below the high.
